Zur Kurzanzeige

2009-11-30Zeitschriftenartikel DOI: 10.1111/j.1469-0691.2009.03097.x
Community-acquired methicillin-resistant Staphylococcus aureus: What do we need to know?
dc.contributor.authorWitte, Wolfgang
dc.date.accessioned2018-05-07T14:16:39Z
dc.date.available2018-05-07T14:16:39Z
dc.date.created2010-12-07
dc.date.issued2009-11-30none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/resA6hlHbrFyk/PDF/28dEXUKJbmftk.pdf
dc.identifier.urihttp://edoc.rki.de/176904/768
dc.description.abstractCommunity-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has become a matter of concern worldwide, in particular in the USA. For the analysis of emergence and spread, clear definitions based on epidemiological origin are needed for discrimination between CA-MRSA, healthcare-associated community MRSA, and healthcare-associated MRSA (HA-MRSA). Although its role in pathogenesis is currently under debate, the capability for Panton-Valentine leukocidin formation is associated with the majority of CA-MRSA isolates from North America and from Europe. Most CA-MRSA isolates are attributed to clonal lineages different from HA-MRSA; there are, however, clonal lineages from which both HA-MRSA and CA-MRSA have been reported (e.g. ST1, ST5, ST8, and ST22); CA-MRSA ST8 (USA300), which is most frequent in the USA, has meanwhile been reported from Europe. CA-MRSA ST80 is widely disseminated in Europe; because of its pronounced oxacillin heteroresistance phenotype, cefoxitin-based assays are advisable for reliable detection. So far, CA-MRSA infections seem to be much less frequent in Europe than in the USA, where patients with particular predispositions and low social status are at especial risk.eng
dc.language.isoeng
dc.publisherRobert Koch-Institut, Infektionskrankheiten / Erreger
dc.subjectHumanseng
dc.subjectGenotypeeng
dc.subjectRisk Factorseng
dc.subjectEurope/epidemiologyeng
dc.subjectCross Infection/microbiologyeng
dc.subjectCross Infection/epidemiologyeng
dc.subjectBacterial Typing Techniqueseng
dc.subjectDNA Fingerprintingeng
dc.subjectCommunity-Acquired Infections/epidemiologyeng
dc.subjectCommunity-Acquired Infections/microbiologyeng
dc.subjectMethicillin-Resistant Staphylococcus aureus/classificationeng
dc.subjectMethicillin-Resistant Staphylococcus aureus/isolation & purificationeng
dc.subjectStaphylococcal Infections/epidemiologyeng
dc.subjectStaphylococcal Infections/microbiologyeng
dc.subjectMethicillin-Resistant Staphylococcus aureus/pathogenicityeng
dc.subjectMicrobial Sensitivity Tests/methodseng
dc.subjectBacterial Toxins/biosynthesiseng
dc.subjectExotoxins/biosynthesiseng
dc.subjectLeukocidins/biosynthesiseng
dc.subjectNorth America/epidemiologyeng
dc.subjectVirulence Factors/biosynthesiseng
dc.subjectbeta-Lactams/pharmacologyeng
dc.subject.ddc610 Medizin
dc.titleCommunity-acquired methicillin-resistant Staphylococcus aureus: What do we need to know?
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10011756
dc.identifier.doi10.1111/j.1469-0691.2009.03097.x
dc.identifier.doihttp://dx.doi.org/10.25646/693
local.edoc.container-titleClinical Microbiology and Infection
local.edoc.container-textWitte, W. Community-acquired methicillin-resistant Staphylococcus aureus: What do we need to know? (2009) Clinical Microbiology and Infection, 15 (SUPPL. 7), pp. 17-25.
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2009.03097.x/abstract;jsessionid=8B8D111ADE7B2FE76B2F188A18D10168.d02t02
local.edoc.container-publisher-nameWiley
local.edoc.container-volume15
local.edoc.container-issueSupplement 7
local.edoc.container-year2009

Zur Kurzanzeige